All In Biotech

Drug Trial Radar · NCT06141473

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,655 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,655

Actual

Start

Dec 13, 2023

Primary completion

May 6, 2027

Study completion May 6, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This event-driven study will have variable duration depending on the recruitment rate, the event rate, the study discontinuation rate and the 12-month minimum treatment duration. Different participants will have different study durations. The last participant randomized will have at least 12 months of study duration, and assuming a 28-month recruitment period, the first participant randomized will have 40 months or longer of study duration. * The study intervention duration will vary similarly as the study duration. * The scheduled visits will include monthly visits for the first 6 months and quarterly visits thereafter until the common end of study (EOS), or premature end of treatment (pEOT) after which 3 follow-up visits will be performed

Conditions

  • Multiple Sclerosis

Interventions

  • FrexalimabDrug

    SAR441344 Solution for IV infusion

  • TeriflunomideDrug

    Aubagio oral tablet

  • Placebo infusionDrug

    Solution for IV infusion

  • Placebo tabletDrug

    Oral tablet

  • MRI contrast-enhancing agentsDrug

    IV, as per respective label

  • CholestyramineDrug

    oral, 8 g 3 times daily for 11 days for accelerated elimination procedure (4 g 3 times daily for 11 days in case of intolerance). The teriflunomide local label should be followed.

  • Activated charcoalDrug

    oral, 50 g every 12 hours for 11 days for accelerated elimination procedure. The teriflunomide local label should be followed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized relapse rate (ARR) during the study period assessed by protocol defined adjudicated relapsesTime frame: Until Week 156

Locations

382 sites in 41 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham- Site Number : 8401135

    Birmingham, Alabama

  • North Central Neurology Associates- Site Number : 8401100

    Cullman, Alabama

  • Alabama Neurology Associates- Site Number : 8400115

    Homewood, Alabama

  • St. Joseph's Hospital and Medical Center- Site Number : 8401139

    Phoenix, Arizona

  • Perseverance Research Center- Site Number : 8401138

    Scottsdale, Arizona

  • Clinical Endpoints- Site Number : 8400050

    Scottsdale, Arizona

  • The Neurology Center of Southern California - Carlsbad- Site Number : 8400023

    Carlsbad, California

  • University of California Irvine - School of Medicine- Site Number : 8401143

    Irvine, California

  • Multiple Sclerosis Center of California - Laguna Hills- Site Number : 8401122

    Laguna Hills, California

  • Chemidox Clinical Trials- Site Number : 8401157

    Lancaster, California

  • Hoag Memorial Hospital Presbyterian- Site Number : 8401031

    Newport Beach, California

  • Private Practice - Dr. Regina Berkovich- Site Number : 8400005

    West Hollywood, California

  • University of Colorado - Anschutz Medical Campus- Site Number : 8401001

    Aurora, Colorado

  • Advanced Neurology of Colorado- Site Number : 8401148

    Fort Collins, Colorado

  • Hartford Healthcare Medical Group- Site Number : 8401069

    Norwich, Connecticut

  • New England Institute for Clinical Research- Site Number : 8400114

    Stamford, Connecticut

  • MedStar Georgetown University Hospital- Site Number : 8400044

    Washington D.C., District of Columbia

  • Neurology of Central Florida- Site Number : 8401147

    Altamonte Springs, Florida

  • Neurology Offices of South Florida - Boca Raton- Site Number : 8401169

    Boca Raton, Florida

  • First Choice Neurology - Espinosa Neuroscience Institute- Site Number : 8401071

    Boca Raton, Florida

  • Nova Clinical Research - Bradenton- Site Number : 8400189

    Bradenton, Florida

  • Mayo Clinic in Florida- Site Number : 8401093

    Jacksonville, Florida

  • Neurology Associates - Maitland- Site Number : 8400010

    Maitland, Florida

  • University of Miami Hospital- Site Number : 8401177

    Miami, Florida

  • Design Neuroscience Center- Site Number : 8401191

    Miami Lakes, Florida

  • Orlando Health Neuroscience Institute - Downtown Pavilion- Site Number : 8400060

    Orlando, Florida

  • Axiom Clinical Research of Florida- Site Number : 8400049

    Tampa, Florida

  • University of South Florida- Site Number : 8400013

    Tampa, Florida

  • Palm Beach Neurology- Site Number : 8401105

    West Palm Beach, Florida

  • Velocity Clinical Research - Savannah Neurology- Site Number : 8400061

    Savannah, Georgia

  • Joi Life Wellness Group LLC- Site Number : 8401192

    Smyrna, Georgia

  • NorthShore Medical Group - Evanston ( Endeavor Health)- Site Number : 8401111

    Evanston, Illinois

  • Consultants in Neurology- Site Number : 8401020

    Northbrook, Illinois

  • Springfield Clinic 1st - 900 Building- Site Number : 8400043

    Springfield, Illinois

  • IU Health Physicians - Fort Wayne - Hope Drive- Site Number : 8400058

    Fort Wayne, Indiana

  • Neuroscience Institute Center- Site Number : 8400053

    Merrillville, Indiana

  • University of Iowa- Site Number : 8400029

    Iowa City, Iowa

  • University of Kansas Medical Center- Site Number : 8400084

    Kansas City, Kansas

  • Kc Research Center- Site Number : 8400032

    Roeland Park, Kansas

  • Baptist Health Lexington- Site Number : 8401149

    Lexington, Kentucky

Showing 40 of 382 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.